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Abstract
Background: Significant gaps remain regarding the pathomechanisms underlying the autoimmune response in
vitiligo (VL), where the loss of self-tolerance leads to the targeted killing of melanocytes. Specifically, there is
incomplete information regarding alterations in the systemic environment that are relevant to the disease state.
Methods: We undertook a genome-wide profiling approach to examine gene expression in the peripheral blood
of VL patients and healthy controls in the context of our previously published VL-skin gene expression profile.
We used several in silico bioinformatics-based analyses to provide new insights into disease mechanisms and
suggest novel targets for future therapy.
Results: Unsupervised clustering methods of the VL-blood dataset demonstrate a “disease-state”-specific set of
co-expressed genes. Ontology enrichment analysis of 99 differentially expressed genes (DEGs) uncovers a down-regulated
immune/inflammatory response, B-Cell antigen receptor (BCR) pathways, apoptosis and catabolic processes in VL-blood.
There is evidence for both type I and II interferon (IFN) playing a role in VL pathogenesis. We used interactome analysis to
identify several key blood associated transcriptional factors (TFs) from within (STAT1, STAT6 and NF-kB), as well as “hidden”
(CREB1, MYC, IRF4, IRF1, and TP53) from the dataset that potentially affect disease pathogenesis. The TFs overlap with our
reported lesional-skin transcriptional circuitry, underscoring their potential importance to the disease. We also identify a
shared VL-blood and -skin transcriptional “hot spot” that maps to chromosome 6, and includes three VL-blood dysregulated
genes (PSMB8, PSMB9 and TAP1) described as potential VL-associated genetic susceptibility loci. Finally, we provide
bioinformatics-based support for prioritizing dysregulated genes in VL-blood or skin as potential therapeutic targets.
Conclusions: We examined the VL-blood transcriptome in context with our (previously published) VL-skin transcriptional
profile to address a major gap in knowledge regarding the systemic changes underlying skin-specific manifestation of
vitiligo. Several transcriptional “hot spots” observed in both environments offer prioritized targets for identifying disease risk
genes. Finally, within the transcriptional framework of VL, we identify five novel molecules (STAT1, PRKCD, PTPN6, MYC and
FGFR2) that lend themselves to being targeted by drugs for future potential VL-therapy.
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Background
Vitiligo vulgaris (non-segmental vitiligo) is a socially
debilitating depigmenting disorder with a prevalence of
0.5–1% in the world population without a pronounced
gender bias [1–5]. VL is an acquired, chronic skin and hair
condition characterized clinically by loss of skin pigment
(melanin), which, if untreated, is typically progressive and
irreversible.
The autoimmune hypothesis of VL has the widest
support. Autoantibodies against membranous compo-
nents of melanocytes were found to be present in
patient sera [6–8], and have recently been investigated
as predictors of disease progression [9]. Several auto-
immune comorbidities including autoimmune thyroid
disease, pernicious anemia, systemic lupus erythemato-
sus (SLE), and Addison’s disease have also been
reported in association with VL [10–14]. Moreover, 20%
of patients have at least one first-degree relative with VL
and other autoimmune disorders (AID) [15, 16], support-
ing the notion of shared genetic factors across various
diseases. Similarities in pathogenetic mechanisms with
alopecia areata suggest new treatment modalities [17].
However, the high degree of familial aggregation has a
non-Mendelian pattern of inheritance which is indicative
of VL being polygenic with the influence of a large
number of factors in nature [18, 19]. Several putative
susceptibility loci have been reported, [20–29] including
human leukocyte antigen (HLA)-associated genes such as
HLA-A2, HLA-DR4 and HLA-DR7 alleles. [20, 30, 31]
Non-HLA immune regulators such as ACE, CAT, CTLA4,
ESR, MBL2, NALP1, FOXP1 and IL2RA [32, 33] and genes
including DDR1, XBP1, NLRP1, PTPN22, and COMT have
also been associated with VL [34].
The literature around VL suggests a generalized immune
dysregulation that is at least in part genetically based,
resulting in humoral [35] and/or cellular (T-cell) immune
responses [36–40] directed at melanocytes. Both innate and
adaptive immunity appear to play a role in disease progres-
sion [20]. Several antigenic proteins coded by genes such as
MLANA/MART1, PMEL (melanosome related) as well as
TYR, TYRP1 and TH (tyrosine related) have been identified
in vitiligo. There is evidence for a key role of cytotoxic T
lymphocytes (CD8 +T cells) as well as cytokines including
interferon-gamma (IFN-γ) in VL pathogenesis [40–51].
Nonetheless, despite a plethora of scientific literature, the
full complement of genetic elements of susceptibility, and
their role in disrupting immune (and non-immune) path-
ways remains to be clarified.
To advance the investigation of the genetic basis for dis-
ease, we examined differential gene expression in the per-
ipheral blood of patients diagnosed with non-segmental VL
as compared with healthy control individuals and placed this
information in context of our previous gene expression ana-
lysis in VL skin. We integrated the transcriptional data with
functional annotations, clinical criteria and knowledge of VL
genetics in an in silico bioinformatics-based approach to de-
velop a more comprehensive framework of disease through
which novel molecules could be proposed for future tar-
geted therapy. The in silico interactome analysis allowed us
to define “over-connected” key transcriptional drivers of dys-
regulated pathways/processes in non-segmental vitiligo. We
found a total of 12 VL-blood (6) and -skin (6) transcriptional
“hot spots” offering several genes that can be prioritized
targets for identifying disease risk genes in future. Finally,
we carefully prioritize 5 molecular targets from VL-skin or
blood (STAT1, PRKCD, PTPN6, MYC and FGFR2) that can
potentially explored as VL therapies.
Results
Unbiased analysis separates samples based on
“disease-state”
Gene expression variations from peripheral blood is suf-
ficient to segregate VL patients from healthy controls in
a non-supervised hierarchical clustering analysis (Fig. 1a).
Within this “disease-state” related signature, we subse-
quently report a group of 319 downregulated transcripts
that is significantly enriched in Gene Ontology (GO)
biological processes (BPs) correlated with regulation of
immune response, cell activation, response to virus,
leukocyte activation as well as inflammatory response,
among others (Additional file 1: Table S1). Principal
components analysis (PCA) showed a spatial separation
of samples without outliers or batch effects (Fig. 1b). In
summation, we were able to assign a blood gene expres-
sion signature capable of separating VL patients and
healthy controls using unsupervised analytical methods.
Pathways and processes based enrichment analyses of
VL-DEGs
“Disease-state” was the largest source of variation capable
of separating VL patients from healthy controls. Ninety-
nine non-redundant differentially expressed genes (DEGs)
(p-value <0.05, fold change (FC) cut off≥±1.4) [4 up-
regulated in patients (UIP) and 95 down-regulated in patients
(DIP)] distinguished the two groups. The complete DEGs list
is included in Additional file 2: Table S2. The top up- and
down- regulated genes are included in Table 1a-b. Two
members of the cytochrome P450 superfamily, CYP3A5 (FC
= 1.5) and CYP1B1 (FC= 1.5), were among the top upregu-
lated genes, and genes encoding IFN-induced proteins, IFIT1
(FC= -4.0) IF144L (FC= -4.0), IFIT3 (FC= -3.5) and IFITM2
(FC= -2.7), were among the top down-regulated genes.
DEGs were processed through an "ontology enrich-
ment analysis" via MetaCore (Fig. 2a-d) and DAVID
(Additional file 3: Table S3 a, b) to identify prominent
disease-related biological pathways/processes to better
understand the pathobiology underlying vitiligo (Fig. 3a-d).
Canonical pathways related to immune response including
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Fig. 1 Unsupervised hierarchical clustering of VL-blood. Unsupervised hierarchical cluster analysis of the 1346 most variably expressed genes across
the 14 arrays (blood samples of 8 VL patients and 6 healthy controls) was performed. a The dendrogram demonstrates a clustering of VL patients from
healthy individuals revealing a molecular classification based on “disease-state”. b Principal components analysis (PCA) displays a scatter plot showing
clear spatial separation of the samples (octahedrons) that are connected to a centroid sphere, with no outliers; In the 3-dimensional plot, the three
principal components PC#1, #2 and #3 of all samples with all probeset IDs and their respective expression variations are plotted on the x-, y- and
z- axes. The total percentage of PCA mapping variability is 67.9%. Color assignations of vitiligo patient (orange) and healthy controls (green) were made
after examination of distribution of samples
Table 1 (a) Top upregulated and (b) top down-regulated DEGs in vitiligo (VL)-blood expression profile
Entrez ID Gene Symbol Gene Title p-value Fold-Change
a
2201 FBN2 fibrillin 2 0.0345 1.5
1577 CYP3A5 cytochrome P450, family 3, subfamily A,
polypeptide 5
0.0315 1.5
23253 ANKRD12 ankyrin repeat domain 12 0.0236 1.4




9636 ISG15 ISG15 ubiquitin-like modifier 0.0172 −4.2
3434 IFIT1 interferon-induced protein with tetratricopeptide
repeats 1
0.0168 −4.0
710 SERPING1 serpin peptidase inhibitor, clade G (C1 inhibitor),
member 1
0.008 −4.0
10964 IFI44L interferon-induced protein 44-like 0.0283 −3.6
4599 MX1 myxovirus (influenza virus) resistance 1,
interferon-inducible protein p78 (mouse)
0.0098 −3.5
3437 IFIT3 interferon-induced protein with tetratricopeptide repeats 3 0.0133 −3.5
4277 MICB MHC class I polypeptide-related sequence B 0.0085 −3.3
653361///654816///654817 NCF1///NCF1B///NCF1C neutrophil cytosolic factor 1///neutrophil cytosolic factor
1B pseudogene///neutrophil
0.0436 −2.7
8638 OASL 2′-5′-oligoadenylate synthetase-like 0.0334 −2.7
10581 IFITM2 interferon induced transmembrane protein 2 0.0342 −2.7
Fold Change; a “positive” fold change indicates an upregulation and a “negative” fold change indicates a down-regulation in peripheral blood of VL patients vs.
healthy controls
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IFN α and β, BCR, interleukins, antiviral actions of IFNs,
and NF-κB, and stress related apoptosis were among the
most enriched in the VL-blood dataset (Fig. 2a, b). The
significance of male sex-related process network (Fig. 2c) is
not completely understood at this time since there is no
reported sex-bias for VL [1]. Enriched diseases, such as
those related to connective tissue (37 DEGs), SLE (30
DEGs) and autoimmune diseases (AID) (39 DEGs) (Fig. 2d)
further support the relevance of our data based on reports
of comorbidity in vitiligo patients [52–54].
More than 50% of the VL-blood DEGs (51 DEGs; 50
DIP and 1 UIP) were associated with a prominent dys-
regulated immune system (Fig. 3a) which could be
broadly divided into several categories: a) Type I IFN
signaling (IFN α/β) [IFIT1, IFITM2, IRF9, ISG15, ISG20,
MX1 MX2, OASL, PTPN6, PSMB8, (Additional file 4:
Figure S1)]; b) Type II IFN (IFN-γ) signaling pathway
[IRF9, PRKCD, EIF2AK2 (PKR), STAT1 (Fig. 4)]; c) IFN
signaling related to inflammation [MICB, IRF9, ISG20,
STAT1, TAP1, MX2, IFI44, PTPN6 (Fig. 3b)]; d) Cytokine
related pathways (28 in total) (Fig. 3c) (IL-13 signaling
(STAT1, PTPN6, STAT6, PRKCD] and IL-2 activation
(NFKB2, HMGA1, PTPN6 and SYK, among others). Ex-
pression of the 99 DEGs was tightly coordinated across
all samples supporting their use as potential biomarkers
of the “disease-state” in peripheral blood of patients
(Additional file 5: Figure S2).
Several down-regulated genes in VL patients were
involved in catabolic processes such as negative regulation
of cellular protein, interferon stimulated gene-15 (ISG-15)
protein conjugation, and proteolysis (Fig. 3d). Addition-
ally, FCGR2B, NCF1, FCGR1A, PRKCD, and SYK form
part of the Fc gamma R-mediated phagocytosis pathway,
(Additional file 3: Table S3a) and MICB, NFKB3, PSMB9,
STAT1 and TAP1 are associated with antigen presentation
(Fig. 2c), which are all indicative of disrupted protein
Fig. 2 Functional annotation and pathway-based analysis of VL-blood associated transcriptional profile. Gene expression values from peripheral blood
samples of 8 VL patients and 6 healthy individuals were compared, generating a trimmed list of 99 DEGs (4 up-and 91 down-regulated). Algorithms
use the uploaded VL-blood associated DEGs as the input list and map each gene to a network object in the MetaCore database. Pathway and network
analysis of the VL-blood transcriptional profile demonstrate an enrichment of the following categories: (a) canonical pathways (b) GO processes (c)
process networks and (d) disease by biomarkers. Top ten enrichments are sorted and ranked by p-value shown on a logarithmic scale. A lower p-value
indicates higher statistical significance
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breakdown accompanied by faulty antigen processing and
presentation.
In silico analyses to investigate functionality of DEGs
VL-specific gene regulation was evaluated through an
enrichment by “protein function” revealing a significantly
high number (14) of transcription factors (TFs) and en-
zymes (18) (Additional file 6: Table S4). We prioritized po-
tentially relevant individual genes, or hubs where essential
genes are highly connected [55]. The topology uncovered
a higher level of in-coming and out-going connections to
and from the VL-dataset to the metabase with a concomi-
tant higher clustering coefficient than either only among
objects in the metabase or within the VL-blood experi-
mental dataset (Additional file 7: Table S5a). Our analysis
revealed 16 DEGs (IRF9, STAT1, FCGR2B, PRKCD,
PSMB9, PSMB8, PTPN6, MX1, MX2, IFIT1, TOMM34,
IFIT3, SERPING1, NCF4, TAP1 and ISG15) in the VL-
blood profile (representing TFs, receptors, kinases, prote-
ases, phosphatases, enzymes and other general proteins)
that are significantly “over-connected” with objects both
within the VL-blood profile as well as the larger metabase
(Table 2). STAT1 and IRF9 are the most significant TFs
from the VL-blood experimental dataset (Additional file 7:
Table S5b) that form a central hub of in-coming and out-
going (positive and negative) interactions with the “over-
connected” objects (Additional file 8: Figure S3). The net-
work includes portions of several canonical pathways such
as IFN-α-IRF9-IFN-β, IFN-β-STAT1-MxA, IFN-γ-IFN-γ
receptor-MxA, major histocompatibility complex (MHC
class I) interactions as well as CASP8-cyt c-CASP9 tether-
ing biological processes such as responses to immunity,
defense, stress, signal transduction, apoptosis and regula-
tion of proteolysis.
We investigated networks associated with TF encoding
genes in the active dataset of potential importance to VL-
blood pathology, and subjected the DEGs list to the “tran-
scriptional regulation network” algorithm in MetaCore.
Additional file 9: Table S6 summarizes 15 top scoring key
TFs linked to networks tethering disease-related biological
processes. Apart from significantly “over-connected” TF
encoding genes such as STAT1, IRF9 and NF-kB from
within the VL-blood dataset, additional but “hidden” TFs
such as CREB1 MYC, IRF4, IRF1, SP1, and TP53 among
others were revealed, echoing similar results obtained in
our VL-skin analysis [56] where we had described MYC as
Fig. 3 Disease-related GO pathways and processes enriched in VL-blood profile. Robust signals of: (a) immune system (51 DEGs), (b) IFN signaling
and inflammation (14 DEGs), (c) response to cytokine (28 DEGs), and (d) protein catabolic process (34 DEGs), are revealed in the VL-blood DEGs.
In the heat maps, red indicates upregulation while blue indicates down-regulation and white indicates unchanged expression. The blood samples
cluster into VL patients (orange) and healthy controls (green). Expression value intensities are illustrated by the color of the scale with a range of
-3.0 to +3.0 on a log scale
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a central TF in VL-pathology, as well as highlighted the
relevance of significant “hidden” TFs. In summation,
integrating our TF data from both VL-blood and skin
(systemic and target tissue milieu) we find shared TF
genes such as MYC, CREB1, TP53, SP1, ESR1, and STAT1,
among others (which are either included/hidden in/from
the VL-blood/skin dataset) that might be further evidence
for their essential role in the transcriptional configuration
underlying pathogenesis in VL. Figure 5 reveals TFs such
as CREB1, MYC, IRF4, STAT1 and NF-kB as hubs of in-
and out- going interactions with several down-regulated
genes in the VL-blood transcriptional profile.
Searching for essential molecules for targeted VL-therapy
In a search for essential VL-related molecules, we selected
5 DEGs: STAT1, PRKCD and PTPN6 from the blood as
well as MYC and FGFR2 from the skin transcriptional
profiles. These molecules are strongly implicated as key
players in the disease based upon the observations of: 1)
dysregulated expression in VL skin or blood; 2) inclusion
in disease-related pathways and processes; and 3) in-silico
bioinformatics-based analyses highlighting functional
significance. Network analysis starting with these five mol-
ecules (STAT1, PRKCD, PTPN6, MYC and FGFR2) as seed
nodes, revealed them as reaction hubs with in-coming and
out-going links (positive and negative influence) to several
objects from the VL-skin and blood datasets as well as the
larger metabase including portions of several canonical
pathways (Fig. 6a). These pathways are associated with
molecules such as IFN-γ, interleukins, growth and death
receptors, caspases, kinases and transcriptional factors
(Fig. 6b). Some of the VL-related GO biological processes
tethered by these molecules are positive regulation of
cellular metabolic process, response to stress, immune
response, signal transduction, defense, cell proliferation as
well as apoptosis, among others. Finally, the five key func-
tional molecules are involved in a significant number of
pairings with other “over-connected” objects. Additional
file 10: Table S7 lists pairs of significantly connected
nodes/objects within the VL-blood dataset that could
interact with each other to regulate larger networks.
STAT1, with 18 interactions was found to be involved in
the most number of pairings, followed by PRKCD, IRF9
and ISG15.
Chromosomal “hot spots”: comparison with literature
Next, we leveraged our VL-blood associated transcrip-
tional profile to map chromosomal areas with an over-
representation of probe expression changes as a function
of presence of the disease. There is a high expectation of
finding disease-associated genetic variations in such
transcriptionally active regions, called “hot spots” as
Fig. 4 IFN-gamma signaling pathway. The IFN-γ signaling pathway is one of the top canonical pathways enriched (p-value 0.0001, FDR 0.005) in
the VL-blood profile. Histograms of down-regulated genes from VL-blood (circled in black) are demonstrated in the map. The height of the
histograms corresponds to the relative expression value for a particular gene/protein. Objects and interactions as well as direction of regulation
are described in the legend
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demonstrated earlier [56–58]. We identified 6 such re-
gions on chromosomes 1, 6, 9, 10, 17 and 21 harboring a
total of 35 down-regulated VL-blood DEGs (Fig. 7a, b).
Three “hot spot’ associated genes, PSMB8 (chr6p21.3),
PSMB9 (chr6p21.3) and TAP1 (chr6p21.3) overlap with
putative VL susceptibility loci [56, 59, 60]. Although HLA-
associated genes were not found in our transcriptional
dataset, the one transcriptional “hot spot” that is overlap-
ping in both VL-blood and -skin expression profiles, maps
to chromosome 6 (chr6p24-q15) and spans the HLA
region including, discoidin domain receptor tyrosine
kinase 1 (DDR1; chr6p21.33) that has been reported as the
strongest VL-susceptibility locus [60].
Interestingly, the 35 DEGs mapping within the 6 “hot
spots” tether many of the statistically enriched immune/in-
flammatory canonical pathways and processes such as B-
cells-, CD4+ T-cells, TNF-R2, IL-2, IL-33 and IL-17 signal-
ing- as well as stress induced apoptosis (Additional file 11:
Figure S4 a-d). The canonical IL-33 signaling pathway
enriched in the 35 DEGs included in the VL-blood “hot
spots” is coincident with our earlier findings in VL-skin
transcriptional profile and linked to inflammation [56]. The
IL-17 signaling pathway has also been increasingly
implicated in several AIDs including vitiligo [61]. The
remaining 64 VL-skin DEGs identified in our present ana-
lysis that did not map within a “hot spot” were enriched in
immune related pathways and processes including the IFN
α, β and γ, viral process, IL-4, IL-5, and IL-13 mediated in-
flammatory signaling, as well as negative regulation of cell
proliferation. Networks starting with the 64 DEGs outside
the “hotspots” tether BPs such as chromatin assembly or
disassembly, collagen catabolic processes (data not shown).





Gene Title Object name Fold
change
A n R N E Ratio z-score p-value
TFs IRF9 interferon regulatory factor 9 IRF9 −1.7 7 102 60 26494 0.231 30.3 14.1 3.32E-09
STAT1 signal transducer and activator
of transcription 1, 91kDa
STAT1 −2.6 22 102 575 26494 2.214 9.9 13.5 4.04E-16




−1.4 2 102 35 26494 0.135 14.8 5.1 0.0080
Kinases PRKCD protein kinase C, delta PKC-delta −1.7 8 102 386 26494 1.486 5.4 5.4 0.0001
Proteases PSMB9 proteasome (prosome, macropain)
subunit, beta type, 9
PSMB9 −1.7 3 102 38 26494 0.146 20.5 7.5 0.0004
PSMB8 proteasome (prosome, macropain)
subunit, beta type, 8
PSMB8(LMP7) −1.6 2 102 30 26494 0.115 17.3 5.6 0.0059
Phosphatases PTPN6 protein tyrosine phosphatase,
non-receptor type 6
SHP-1 −1.9 5 102 200 26494 0.770 6.5 4.8 0.0010
Enzymes MX1; MX2 myxovirus (influenza virus)
resistance 2 (mouse)
MxA −3.5 ; -2.2 3 102 57 26494 0.219 13.7 6.0 0.0013
Others IFIT1 interferon-induced protein
with tetratricopeptide repeats 1
IFIT1 −4.0 4 102 15 26494 0.058 69.3 16.4 2.74E-07
TOMM34 translocase of outer mitochondrial
membrane 34
TOM34 −1.6 2 102 21 26494 0.081 24.7 6.8 0.0029
IFIT3 interferon-induced protein with
tetratricopeptide repeats 3
RIG-G −3.5 6 102 66 26494 0.254 23.6 11.4 2.11E-07
SERPING1 serpin peptidase inhibitor,
clade G (C1 inhibitor), member 1
C1 inhibitor −4.0 2 102 23 26494 0.089 22.6 6.4 0.0035
NCF4 neutrophil cytosolic factor 4,
40kDa
p40-phox −1.8 2 102 23 26494 0.089 22.6 6.4 0.0035
TAP1 transporter 1, ATP-binding
cassette, sub-family B (MDR/TAP)
TAP1 (PSF1) −1.6 4 102 51 26494 0.196 20.4 8.6 4.5E-0
ISG15 ISG15 ubiquitin-like modifier ISG15 −4.2 8 102 256 26494 0.986 8.1 7.1 6.83E-06
Explanation of each column
Protein Function: overall associated functions with proteins; Gene IDs in active data sets: gene symbol associated with the VL skin transcriptional profile; Gene
Title: Full name of gene; Object Name: network object in metabase; Fold change: expression by microarray VL vs control. A: number of network objects in the
activated signatures which interact with the chosen object; n: number of network objects in the signature; R: number of network objects in the background list
which interact with the chosen object; N: total number of protein-based objects in the background list; E (Expected): mean of hypergeometric distribution; Ratio:
connectivity ratio (actual/expected); z-score: (actual-expected)/(standard deviation); p-value: probability to have the value of Actual or higher (lower for negative
z-score) by chance under null hypothesis of no over- or under-connectivity; TFs: Transcription factors
“Over-connected” genes (encoded protein) by “function” is based on the connectivity of genes in the active dataset with genes from the Human Proteome in the MetaCore
database (metabase). We found sixteen (MX1 and MX2 are both in the dataset and map to a group in metabase) significantly over-connected genes in VL-blood
transcriptional profile where the number of observed interactions exceeded the number of expected interactions. There were no under-connected genes observed
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Finally, we compared the full set of 99 VL-blood DEGs
(35 mapping inside “hot spots”, and 64 outside) to a com-
prehensive set of 137 VL-associated DEGs and potential
gene markers compiled from several GWAS and gene ex-
pression studies. Apart from the 3 DEGs (within the “hot
spots”) described above that coincided with VL-associated
susceptibility genes, P2RY14 (purinergic receptor P2Y, G-
protein coupled, 14) was DIP in the present dataset while
being up-regulated in a recent VL-blood microarray study
using pooled case and control samples [62]. No other
overlaps were found with any other study.
Discussion
Major gaps remain in our knowledge regarding how gen-
etic and environmental elements alter gene expression at
the systemic level to promote or prevent vitiligo. We ex-
amined transcriptional profiles from peripheral blood of
non-segmental VL cases and healthy controls (including
11 females and 3 males between the ages of 31–70 years,
Table 3) using several in silico “function based” analyses to
better understand underlying regulatory mechanisms in
VL-pathogenesis. Our strategy was to integrate genetic,
biological and clinical information to identify and
characterize molecular elements of potential disease rele-
vance in the blood. The use of unfractionated skin and
PBMCs for VL-gene expression analysis offers a global
and comprehensive overview of disease-associated tran-
scriptional changes that may be relevant to disease expres-
sion and the identification of disease biomarkers.
VL-pathogenesis, similar to other heterogeneous auto-
immune diseases is multifactorial and polygenic. Unsuper-
vised clustering methods demonstrated a specific “disease-
state” based molecular signature in peripheral blood distin-
guishing VL patients and healthy controls. This signature
could potentially be leveraged to identify biomarkers for
diagnostic, prognostic and classification purposes. Bio-
logical processes (including mostly down-regulated genes)
such as immune/defense response and cell activation were
found to be enriched in both a subset of VL-blood genes
examined from the unbiased hierarchical cluster as well as
the differentially expressed gene profile, reinforcing their
likely importance as central drivers in disease pathogenesis.
Fig. 5 Network analysis of key transcriptional factors (TFs) in VL-blood pathology. The VL-blood DEGs list was analyzed using the “transcriptional
regulation network” algorithm (see Additional file 9: Table S6). Auto-expanded (by one step) network was generated using the top three (CREB1,
MYC and IRF4) TFs associated with disease-related BPs and then merged. STAT1 and NF-kB (from the dataset- orange boxes) as well as CREB1, MYC,
IRF4, (“hidden” from dataset- yellow boxes) are TF hubs revealing a large number of curated interactions directly to and from (direction of arrow)
objects in the VL-blood profile. Each hub is color coded (red = IRF4, blue =MYC, green = CREB1, magenta = STAT1/IRF9/ISG15 complex, variable
colors = NF-kB (connected to several hubs). See Fig. 4 legend for types of objects
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Fig. 6 Network analysis using key molecules in VL pathogenesis. We prioritized five DEGs (STAT1, MYC, PRKCD, PTPN6, and FGFR2) based on combined
transcriptional- (VL-blood and skin) as well as in silico bioinformatics-based analyses. These 5 molecules/proteins were used as seed nodes to construct
a network using the shortest path algorithm with a 2-step connection. Proteins are ordered according to their cellular localization from left to right. All
five prioritized molecules are reaction hubs (blue ovals) where curated interactions are observed with both positive (green lines) and negative effects
(red lines) directly to and from (direction of arrow) the hubs with several objects in the VL-blood profile as well as the larger human proteome data-
base. (a) Portions of several canonical pathways are included in the network (in cyan), (b) a few canonical pathway portions have been traced including
PTPN6-MYC-ELK1, Collagen 1-alpha11/beta1integrin-MYC, PTPN6-JAK2-BCL2 (in magenta) that are involved in immune regulation and inflammation and
others such as CASP8-Cytochrome c-CASP9, Apo2L-DR5-BAX (in orange), are associated with apoptosis and survival. Gene expression data from both VL-
blood and skin profiles are overlaid on the same network. The up- and down-stream interactions revealed by our network analyses may be leveraged
to assess and validate functional consequences of targeting the 5 molecules by therapeutic drugs in future investigations. See Fig. 4 for legend
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Functional annotation of the DEGs using two different
analytical platforms (DAVID and MetaCore) illuminated
systemically perturbed immune/defense response, protein
catabolic processes and antigen processing and presentation
enriched in the predominantly down-regulated genes
of peripheral blood in VL patients, echoing a recent
GWAS study demonstrating an enrichment of similar
immuneregulation-related pathways and processes in
the 48 confirmed vitiligo associated loci [29].
Broadly, our findings strongly support a down-
regulation of both innate and adaptive immune/inflam-
matory response in VL-blood in the context of an accu-
mulation of regulators in the activation of cytoskeletal
remodeling, oxidative stress and apoptosis in VL-skin
where the disease is manifest. These findings indicate
tissue environment-specific changes in the disease and
suggests tightly regulated mechanisms underlying
disease-related pathways. The down-regulation of several
immune system related pathways in VL blood might
represent the susceptibility to the disease in VL patients
at the systemic level. Our experiments do not address
the temporal order of gene expression alterations, but
rather a slice in time. Thus our VL-blood results might
be expected to reveal a pattern of gene dysregulation
that encompasses counter-regulatory molecules/path-
ways in response to an aberrant immune response.
The overlap of several DEGs within VL-blood profile and
disease markers in SLE as well as other AIDs supports
existing literature regarding comorbidities in vitiligo
patients [10, 12, 52, 54]. Nath et al., (2001) reported
evidence of a possible shared genetic effect between vitiligo
and SLE, with a probable common genetic determinant on
chromosome 17p13 (susceptibility gene SLEV1) [53]. In the
present analysis of VL-blood, 4 dysregulated genes mapped
to the “hot spot” on chromosome 17 in the neighborhood
of SLEV1, indicating perturbation in the same region.
Both innate and adaptive immune response are induced
by pleiotropic cytokines known as IFNs that exhibit
Fig. 7 Genome-wide chromosomal distribution of VL-blood and skin DEGs. (a) Chromosomal locations of the 99 VL-blood DEGs are colored in
bold black vertical bars versus the other genes which are grey. The upright bars above and below the parallel lines represent genes either on the
forward or reverse strand. Each horizontal black line corresponds to one chromosome. The VL-blood DEGs were mapped to chromosomes with
significant stretches, considered transcriptional “hot spots” marked by 6 red boxes. (b) A total of 35 dysregulated VL-blood genes are located in
the 6 VL-blood “hot spots” with PSMB8, PSMB9 and TAP1 (bold) on chromosome 6 reported previously as potential VL-associated genetic loci.
Subsequently we overlaid the 6 transcriptional “hot spots” from our previous VL-skin analysis (6 blue boxes) on the VL-blood chromosomal map.
The chromosome # and locus of each transcriptional “hot spot” from VL blood (red) and skin (blue) is defined. The transcriptionally active “hot
spots” on chromosome 6 overlaps between the VL-skin and blood gene expression profiles (yellow). Three additional “hot spots” from the two
tissue environments map to the same chromosome but do not overlap with each other (grey)
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antiviral, anti-proliferative and immunomodulatory effects.
The migration of transcriptional activator STAT1 into the
nucleus to activate genes involved in cell proliferation and
viability can be activated by Type 1 or Type II IFN path-
ways [63, 64]. Previous investigations have demonstrated
that IFN-γ concentrations as well as the IFN-γ: IL-10 ratio
in serum plays a major role in VL-induced depigmentation
and pathogenesis [47, 65]. Our analysis confirms previous
reports supporting [43, 65, 66] the central role for both IFN
types in vitiligo. Overall, the present study reinforces the
critical role of IFN-γ-chemokine axis for the progression
and maintenance of VL, and illuminates a therapeutic po-
tential [43, 67, 68]. Furthermore, the down-regulation of
TFs such as STAT1, STAT6 and NF-kB in the VL-blood
dataset might be additional indication of the attempt to
counter activate apoptotic signals previously observed in
lesional skin. Our findings allow us to speculate about the
attempt within both the systemic and the target tissue en-
vironment to repair and repopulate cells that are defective,
dying or dead due to disease.
With regards to “hidden” transcriptional factors, we
found several such as CREB1, MYC, IRF4, IRF1, TP53 in
the VL-blood profile that echoed a similar TF circuitry
found in our previous investigation of VL-lesional skin
pathology [56], underscoring the importance of the mech-
anisms relying on the STAT1/IRF9/MYC signaling in the
disease. Several transcription factors, including CREB1
and STAT3 are able to modulate the expression and/or
transcriptional activity of the microphthalmia transcrip-
tion factor (MITF), a master gene for melanocyte survival
[69]. Our VL-skin data previously revealed a down-
regulation of genes involved in terminal differentiation of
melanocytes. This could be due to the lack of melanocytes
in lesional skin as reported in literature [70, 71], or suggest
a key role for the breakdown in the signaling pathway in-
volving MITF and CREB1 in melanogenesis. Our results
allow us to further consider the participation of the TFs
such as CREB1, MYC, IRF4, STAT1/IRF9, IRF1 and TP53
in the regulation of viral processes, IFN signaling pathway,
innate immune response, immune effector processes, re-
sponse to cytokine stimulus, defense response, and cellular
response to Type I and II IFNs. We had previously noted
In VL-skin that melanocytes, immune cells and keratino-
cytes, among other cell types experience proliferative sig-
nals accompanied by a pronounced up-regulation of
nucleotide and protein metabolic processes.
The enriched BCR pathway (including DEGs: FCGR2B,
NFKB2, MAP3K7, SYK and PTPN6) that is part of the
‘adaptive’ cellular response [72] plays a critical role in the
development, survival, and activation of B lymphocytes.
This pathway is composed of membrane immunoglobulin
molecules which bind antigens causing receptor aggrega-
tions and act through several transduction molecules such
as SYK and MAP3K7 that influence TFs such as NF-kB in
Table 3 Demographic data for study subjects
Sample Age (Range in yrs.) Diagnosis Duration
(years)
Current Meds Previous Treatments Past Med History
VL1009B 60–69 Vitiligo 10 None topical and oral steroid HTN
VL1010B 50–59 Vitiligo 2 None steroid (1.5 yrs ago) hypothyroid
VL1016Ba 70–79 Vitiligo 50 ASA, atenolol, lipitor, detrol LA Methoxsalen (45–50 yrs. ago),
none currently
None
VL1017Ba 30–39 Vitiligo 10 PABA, vitamin B12, trazodone
and other antianxiety med
light treatment (6 yrs. ago),
Vit B12 injection
None
VL1018Ba 30–39 Vitiligo 12 None None None
VL1019Ba 30–39 Vitiligo 26 None None Factor V disorder
VL1020B 60–69 Vitiligo 30 None None None





NL1001B 50–59 No disease none none none none
NL1004B 30–39 No disease none none none none
NL1013B 30–39 No disease none none none none
NL1014B 40–49 No disease none none none none
NL1020B 50–59 No disease none none none none
NL1032B 40–49 No disease none none none none
Abbreviations: VL vitiligo, NL normal, B blood, PABA para amino benzoic acid, HTN hypertension, SCC squamous cell carcinoma, ASA amino salicylic acid, LA long
acting. Patients were under no systemic or topical medications for 2 months prior to sampling. aStarred samples are shared between our previous skin and the
present blood analyses. Gender and ethnicity details are withheld to protect patient privacy. While the healthy controls were 100% females, the female to male
ratio in vitiligo patients is 6.2: 3.8. Ethnicity distribution among healthy controls is 67% African American, 17% Caucasian and 17% Asian and among VL patients
50% Caucasians, 25% Hispanics, 12.5% Asian and 12.5% African
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the nucleus, permitting several distinct outcomes, includ-
ing proliferation, differentiation, apoptosis, survival and
tolerance of B cells. The down-regulation of all VL-blood
genes that are represented in the pathway might contrib-
ute to the switchboard functioning of the BCR pathway,
enabling it to selectively turn on a specific signaling
pathways by keeping others quiescent [73, 74].
Studies have demonstrated the usefulness of using gene
expression data to successfully prioritize candidate genes
for disease-associated single nucleotide polymorphisms in
genome-wide studies [75]. Our analysis mapped 6 “hot
spots” as transcriptionally active sites with TAP1 (trans-
porter 1, ATP-binding cassette, subfamily B member),
PSMB8 and PSMB9 (proteasome subunit, beta type, 8 and
9) coinciding with previously reported VL susceptibility
loci [76]. These three genes are linked to macromolecular
catabolic processes associated with proteasomes which
normally protect against the development of T-cell medi-
ated AIDs [77]. Proteasomes are responsible for degrading
short-lived cytoplasmic proteins into peptides [78].
Among its 28 subunits, the 20S proteasome includes two
subunits known as PSMB8 (LMP7) and PSMB9 (LMP2).
Anomalies in TAP1 and PSMB proteins have been
reported to be associated with vitiligo along with several
other AIDs such as Sjogren’s syndrome, type 1 diabetes,
juvenile rheumatoid arthritis, celiac disease, and multiple
sclerosis [79, 80]. TAP1 functions by providing candidate
peptides to MHC-I molecules within the peptide-loading
complex and by transferring antigenic peptides from the
cytoplasm into the endoplasmic reticulum [81]. The sig-
nificance of all three proteasome-related molecules being
down-regulated in blood, might indicate that coordinated
events of healthy antigen processing and presentation
have gone awry in VL patients. Interruption of the self-
antigen presentation pathway on MHC-I has been shown
to be a possible pathway for self-tolerance and autoreac-
tivity against a variety of target organs [82, 83]. Similar to
our published results in VL-skin, the “hot spot” region
mapping to chromosome 6 in VL-blood also covers the
same HLA region coinciding with the strongest genetic
associations of VL [59, 60]. The influence of the HLA
region is also likely connected to its well-established role
in antigen presentation and T cell activation [84].
Working towards personalized alternate therapy choices
in VL, we broadened our search for key molecules related
to the disease that can potentially be targeted by drugs. We
focused on five DEGs (STAT1, PRKCD, PTPN6, MYC and
FGFR2) based on the following criteria: 1) differential ex-
pression in VL-skin or blood; 2) inclusion in disease-related
pathways; 3) interactome analysis highlighting “over-con-
nectivity” in functional interactions; 4) network analysis
demonstrating all 5 targets as interactive hubs, and 5)
paired functional interacting units. Crucial regulatory roles
are indicated for the two transcriptional factors (STAT1 and
MYC), the phosphatase (PTPN6) and kinase (PRKCD) in
VL pathogenesis. Although FGFR2 is not one of the “over-
connected” DEGs, the localization of the disease-related
growth receptor in the membrane with an extracellular
domain capable of being recognized by specific ligands and
drugs, makes it an attractive [85] molecule to investigate as
a potential target. Interestingly, among the five molecules
delineated by the present study (by a combination of tran-
scriptome and bioinformatics analyses), STAT1 is presently
being investigated as a promising target in the treatment of
VL [68, 86]. The lack of FGFR2 expression results in a
melanocyte-related disease such as piebaldism. Overall, we
suggest the following five molecules to be prioritized as
targets for future potential VL-therapy:
1) Signal Transducer and Activator of Transcription 1,
(STAT1) (FC = -2.6; VL-blood) is a 91kDa member
of the STAT family that reacts to cytokines and
growth factors. It is phosphorylated by the receptor
associated kinases and translocates to the cell
nucleus where it acts as a transcription activator
involved in apoptosis. While responding to IFN-γ,
STAT1 is phosphorylated, and regulated by
activation of PRKCD downstream of the activation
of the phosphatidylinositol 3-kinase (PI3K)
signaling pathway. This can result in either pro- or
anti-apoptotic outcomes depending on the cellular
context and other interacting pathways [87, 88].
STAT1 has also been shown to act as a driver in
cancers, modulating downstream MYC expression,
which in turn promotes the capacity for
proliferation, migration, and invasion of cells [89].
STAT1 activation that is essential for IFN-γ signaling
has been targeted by simvastatin in mouse models
(FDA-approved medication for lowering cholesterol
levels) and is currently being investigated [68].
2) Protein Kinase C, delta (PRKCD) (FC = -1.7;
VL-blood) is a member of the family of
serine- and threonine-specific protein kinases that
can be activated by calcium. Human and mouse
studies demonstrate that this kinase is involved
in B cell signaling, regulation of growth, apoptosis,
and differentiation of a variety of cell types [90],
as well as the IFN-γ signaling described above [88].
3) Protein Tyrosine Phosphatase, Non-Receptor Type 6
(PTPN6) (FC = -1.9; VL-blood) encodes for a
member of the protein tyrosine phosphatase (PTP)
family of signaling molecules that regulate a range of
cellular processes such as cell growth, differentiation
and mitotic cycle, while itself being regulated by the
cytokine IFN-α. PTPN6 was shown to be a negative
regulator of EMT transition which is involved in loss
of cell-cell adhesion and increase in cell motility and
reorganization in skin [91]. Cytokine-based therapies
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have the potential to provide novel treatments for
cancer, infectious disease, and AIDS.
4) We have described v-myc avian myelocytomatosis viral
oncogene homolog (c-Myc/MYC) (FC = 1.5;
VL-skin) as an “over-connected” TF in our previous
VL-skin report [56]. It is involved in cell growth,
apoptosis and metabolism. It functions as a
transcription factor regulating specific target genes. The
MYC proto-oncogene has been found to be stimulated
in various animal and human tumors. It is important in
both development as well as cell proliferation.
5) Fibroblast growth factor receptor 2 (FGFR2)
(FC = 1.9 VL-skin) is a highly conserved protein.
It is part of the FGFR family whose members differ
from each other in ligand affinities and tissue
distribution. The maturation and continued existence
of migrating melanoblasts is closely associated with
simultaneous FGFR2 expression and a lack or
dysfunction of the receptor results in maladies
such as piebaldism (related to melanocyte
development), among others [85]. A loss of FGFR2
function is also shown to contribute to melanoma
[92]. FGFR2 has an extracellular portion that interacts
with fibroblast growth factors, setting in motion a
cascade of downstream signals ultimately influencing
mitogenesis and differentiation.
Conclusions and future directions
The present study represents a genome-wide transcrip-
tome analysis of blood, from predominantly female non-
segmental vitiligo patients and healthy controls, exam-
ined in the context of our previous VL-skin report.
Using several in silico bioinformatics-based analyses, we
identify five novel molecules (STAT1, PRKCD, PTPN6,
MYC and FGFR2) that have the potential to be targeted
by drugs for future therapy. Additionally, we reveal mo-
lecular regulators affecting apoptosis, cytoskeletal remodel-
ing, oxidative stress and metabolism in the skin and
immune response in the blood that are suggested to con-
tribute to the autoimmune reaction against melanocytes in
the skin, similar to a recent report [29]. Future work will
involve a larger cohort of different sub-phenotypes of VL
patients, both male and female, accompanied with cell sort-
ing of purified cell populations with the aim of assigning
DEGs to specific candidate cell types. Longitudinal analyses
of VL lesions that are newly developing, flaring or undergo-
ing re-pigmentation may help to illuminate specific
transcriptional changes within a temporal framework of
disease development and progression. On-going integrated
analyses of transcriptional regulation in tissue-specific and
circulatory environments has the potential to clarify details
of molecular interplay that tethers the autoimmune re-
sponse underlying disease pathogenesis in vitiligo. Future
research into available drugs that can target the five vital
disease-linked molecules proposed in this report holds the
promise of expanding efficacious treatment in vitiligo.
Methods
A diagnosis of non-segmental VL (referred to as vitiligo or
VL in this paper) based on established clinical criteria was
the basis for recruitment to the study at the Dermatology
outpatient clinic of New York Presbyterian Hospital-
Cornell University. Ethical guidelines were followed by
obtaining signed consent forms for punch biopsies and
blood draw from patients and healthy controls (IRB #
0998-398). PBMCs were isolated from blood of VL patients
and healthy control individuals that were all off therapy at
the time of sampling. All specimens were snap frozen in li-
quid nitrogen immediately. The procedures for blood and
tissue handling, PBMC extractions, total RNA preparation,
cDNA synthesis have been described before [93–95].
Demographic details with age, duration of disease, ethnicity
and treatment history for each subject that were chosen for
subsequent analysis are presented in Table 3.
Microarray method
The Affymetrix GeneChip Expression Analysis Technical
Manual (Affymetrix, Santa Clara, CA, http://www.affyme-
trix.com) was followed for experimental procedures for
microarray assays as described earlier [56, 94, 95]. Labeled
cRNA was hybridized for 16 h at 45°C to microarrays
(Affymetrix HG-U95Av1_v2). The chips were then washed,
stained and scanned according to manufacturer’s protocol
(Affymetrix Inc., Santa Clara, CA) on the Affymetrix Fluid-
ics Station 750, and scanned by the Affymetrix GeneChip
Scanner 3000.
Microarray data analysis
Gene expression values from lesional/non-lesional skin
(n-16) and blood samples (n = 24) from VL patients and
healthy controls were imported into Partek Genomics
Suite v6.6 (Partek, St Louis, MO) as CEL files. Raw data
preprocessing details have been described earlier [56].
The data was examined using quality control criteria in Par-
tek software. Ten normal blood samples were discarded
from the final differential expression analysis due to a failure
to pass quality control check. Expression data from periph-
eral blood of VL patients (n= 8, 5 females and 3 males) and
healthy controls (n = 6, all females) were finally used for es-
tablishing DEGs with “disease-state” as the greatest source
of variation across all 12,625 probeset IDs. Average expres-
sion levels were distributed similarly across all samples.
Unsupervised hierarchical clustering
The informative probe sets with the most variation
across arrays were selected for ‘unbiased’ hierarchical
cluster analysis using a coefficient of variation filter
greater than 0.12 across all blood arrays. We found 1346
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most variably expressed probeset IDs from peripheral
blood samples of VL cases and controls. A two way
cluster analysis was performed on these probe sets based
on Euclidean distance and centroid linkage (1-r metric)
for samples and average linkage for probeset IDs. Subse-
quently, we examined these 1346 probeset IDs to find a
set of 319 non-redundant transcripts that were down-
regulated in VL patients and functionally annotated
them via DAVID. Principal components analysis was
performed on all 12,625 probeset IDs (transformed and
normalized) to look for key variables in the dataset and
observe batch effects in dataset. We superimposed sam-
ple information using color coding after assessing the
sample separations by the unbiased clustering methods.
Differentially expressed genes (DEGs)
We defined DEGs between VL patients and healthy con-
trols using similar methods as described before [56]. While
controlling the p-value at <0.05, we used a FC cut off ≥ ±1.4
to generate a list of 105 DEGs. A trimmed list of 99 unique
DEGs (upon removing redundancies, non-annotated probe-
set IDs and pseudogenes) was generated and used for all
subsequent analyses. Array data is also internally validated
by examining multiple probeset IDs for the same gene.
When data from all such probes in the experiment are
identified as correlating in an array experiment, there is
higher probability of the finding being real [96]. For e.g.
annotation for Probeset IDs: 263_g_at (FC-1.57), 262_at
(FC =–1.50) and 36685_at (FC = -1.50) were all AMD1
(adenosylmethionine decarboxylase 1). We finally retained
the representative probeset ID associated with the highest
+/-fold change linked with the lowest p-value among the
replicates to generate the list of non-redundant DEGs.
Using both unbiased and supervised methods to reveal cor-
roborating results serves to further bolster the disease-
related findings in our report.
Tools in DAVID [97] (https://david.ncifcrf.gov/) as
well MetaCore™ v6.21 (Thomson Reuters, St Joseph, MI)
(http://www.genego.com) were used for ontology enrich-
ment analyses [98] [99]. Methods were the same as
described earlier [56]. We were able to generate and
analyze several disease-associated canonical pathway maps
in MetaCore database followed by similar investigations in
the Gene Ontology (GO) and KEGG databases.
Chromosomal mapping and interactome/network analyses
We leveraged the VL-blood gene expression data to delin-
eate regions of chromosomal enrichment (“hot spots”) that
contain more dysregulated genes than can be expected by
chance [58, 100]. P-value≤ 0.05 was calculated for all
stretches of chromosomes that contained ≥ 3 DEGs (from
the 99 VL-blood DEGs used for this analysis) and these
significant stretches (“hot spots”) are outlined in boxes
(Fig. 7a). The DEGs in the VL-blood expression profile were
analyzed in the context of all the >12,625 genes on the
array for their chromosomal location enrichment using
DNA-Chip Analyzer (dChip) (www.dchip.org) using in-
structions as detailed in https://sites.google.com/site/dchip-
soft/high-level-analysis/map-genes-to-chromosome. Dupli-
cate probe sets were masked for gene mapping using the
“genome” tool as described earlier [56, 93, 95]. We subse-
quently overlaid the VL-skin chromosomal map on the VL-
blood map to investigate overlapping “hot spots” between
the two environments. In order to find key molecular
elements underlying disease pathology in VL patients we
used an in silico global protein interaction network analysis
of the VL-blood transcriptional dataset [101]. The relative
connectivity of a gene or protein reflects its functional
consequence to VL [102]. It is calculated by the number of
interactions between an experimental gene with the other
genes on the experimental list normalized to the number of
interactions it has with all genes in the human database
(Metabase). One hundred and sixty VL-associated DEGs,
potential biomarkers and susceptibility loci were discovered
from VL-associated genes found by microarray and GWAS
(http://www.genome.gov) [26, 29, 32, 33, 43, 56, 62, 70, 76,
79, 103–135] as well as the metabase and were compared
to our DEGs list to search for overlaps.
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